Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00388180
Status:
COMPLETED
Last Update Posted:
2012-03-19
First Post:
2006-10-13
Brief Title:
An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-blind Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X 20ug or GW501516X 10mg Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigational drugs administered in this study activate proteins called PPARs Data in the scientific literature on PPARs as well as animal data and early clinical data generated by GSK with these drugs suggest that activation of PPARs may cause the body to increase its use of fatty acids for energy and lead to a reduction in body fat There are also data to suggest a role for PPARs in regulating lipid eg cholesterol levels and inflammation These and other activities of PPARs are being further explored in this clinical study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None